Trade, IP And Oncology Deals: What You Need To Know About China And JPM20

 
• By Brian Yang

China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.

China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
CHINA-US TRADE DEAL SIGNED DURING JPM20 UNLIKELY TO IMPROVE IP SITUATION? • Source: Shutterstock

More from China

More from Focus On Asia